Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lead Pb 212 pentixather

A radioconjugate composed of pentixather, a chemokine receptor C-X-C chemokine receptor type 4 (CXCR4)-targeting ligand, conjugated to the alpha-emitting radioisotope lead Pb 212, with potential antineoplastic activity. Upon administration, lead Pb 212 pentixather targets and binds to CXCR4-expressing cancer cells. This allows for the specific delivery of a cytotoxic dose of alpha radiation to CXCR4-expressing cancer cells. CXCR4, a marker of poorly differentiated cells, is overexpressed on various cancer cells, and plays a key role in tumor growth, progression, invasiveness and metastasis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:212-lead pentixather
212Pb-pentixather
lead 212-labeled pentixather
lead Pb 212-pentixather
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search